Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals With Latent Tuberculosis Infection.
Phase of Trial: Phase III
Latest Information Update: 06 Dec 2017
At a glance
- Drugs Isoniazid (Primary) ; Rifapentine (Primary)
- Indications Tuberculosis
- Focus Therapeutic Use
- 01 Dec 2017 Status changed from active, no longer recruiting to completed.
- 20 Nov 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 17 Nov 2014 Planned primary completion date changed from 1 Dec 2017 to 1 Nov 2017 as reported by ClinicalTrials.gov record.